Pembrolizumab for Locally Advanced or Metastatic Urothelial Cancer Where Cisplatin is Unsuitable: An Evidence Review Group Perspective of a NICE Single Technology Appraisal Shijie RenHazel SquiresConstantine Alifrangis Review Article 13 December 2018 Pages: 1073 - 1080
The Clinical and Cost Effectiveness of Inotuzumab Ozogamicin for the Treatment of Adult Relapsed or Refractory B-Cell Acute Lymphoblastic Leukaemia: An Evidence Review Group Evaluation of a NICE Single Technology Appraisal Edward CoxRos WadeSusan Griffin Review Article 19 March 2019 Pages: 1081 - 1091
Cost Effectiveness of Elderly Pneumococcal Vaccination in Presence of Higher-Valent Pneumococcal Conjugate Childhood Vaccination: Systematic Literature Review with Focus on Methods and Assumptions Marina TreskovaStefan M. ScholzAlexander Kuhlmann Systematic Review 26 April 2019 Pages: 1093 - 1127
Estimating Lifetime Benefits Associated with Immuno-Oncology Therapies: Challenges and Approaches for Overall Survival Extrapolations Mario J. N. M. OuwensPralay MukhopadhyayAndrew Briggs Original Research Article Open access 18 May 2019 Pages: 1129 - 1138
Mapping the PedsQL™ onto the CHU9D: An Assessment of External Validity in a Large Community-Based Sample Christine Mpundu-KaambwaGang ChenJulie Ratcliffe Original Research Article 03 June 2019 Pages: 1139 - 1153
Severity-Adjusted Probability of Being Cost Effective Matthijs M. VersteeghIsaac Corro RamosWerner B. F. Brouwer Original Research Article Open access 27 May 2019 Pages: 1155 - 1163
Valuation of EQ-5D-5L Health States in Poland: the First EQ-VT-Based Study in Central and Eastern Europe Dominik GolickiMichał JakubczykMaciej Niewada Original Research Article Open access 03 June 2019 Pages: 1165 - 1176
Cost Effectiveness of Blinatumomab Versus Inotuzumab Ozogamicin in Adult Patients with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia in the United States Thomas E. DeleaXinke ZhangZe Cong Original Research Article Open access 20 June 2019 Pages: 1177 - 1193
